Author information:
(1)UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, 
Switzerland. Electronic address: reinhard.dummer@usz.ch.
(2)Royal North Shore Hospital, Sydney, Australia.
(3)Medizinische Hochschule Hannover, Hannover, Germany.
(4)Sint-Augustinus Ziekenhuis, Antwerp, Belgium.
(5)Division of Medical Oncology, School of Medicine, University of Colorado, 
Aurora, Colorado.
(6)Anti Cancer Institute, Léon Bérard, Lyon, France.
(7)Glasgow Royal Infirmary, Glasgow, United Kingdom.
(8)University Hospital Jena, Jena, Germany; SRH Wald-Klinikum Gera GmbH, Gera, 
Germany.
(9)University Medical Center Mainz, Mainz, Germany.
(10)Department of Dermatology, Andreas Sygros Hospital, University of Athens, 
Athens, Greece.
(11)Fachklinik Hornheide, Münster, Germany.
(12)Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, 
United Kingdom.
(13)Novartis Pharma AG, Oncology Global Development, Basel, Switzerland.
(14)Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
(15)Stanford University School of Medicine, Redwood City, California.
(16)Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 
Brussels, Belgium.
(17)Winship Cancer Institute at Emory University, Atlanta, Georgia.
(18)Dermatologikum Berlin, Berlin, Germany.
(19)Manchester Academic Health Science Centre, University of Manchester, 
Manchester, United Kingdom.
(20)Departments of Dermatology and Head and Neck Surgery, University of Texas MD 
Anderson Cancer Center, Houston, Texas.